Stockscreener 앱 받기
6.40
2.44%
-0.16
시간 외 거래:
6.45
0.05
+0.78%
Abeona Therapeutics Inc 주식(ABEO)의 최신 뉴스
StockWatch: Second Time’s the Charm for Abeona’s Gene Therapy - Genetic Engineering and Biotechnology News
Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease - MSN
Abeona Therapeutics (ABEO) Gains FDA Approval for Gene Therapy | - GuruFocus
Institutional investors control 44% of Abeona Therapeutics Inc. (NASDAQ:ABEO) and were rewarded last week after stock increased 22% - simplywall.st
FDA approves Abeona’s $3.1m cell therapy for rare skin disease - MSN
ABEO: Zevaskyn Approved by FDA Raising Valuation to 11 - Smartkarma
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease - Benzinga
Abeona Therapeutics (ABEO) Sees Price Target Boost Amid FDA Appr - GuruFocus
Abeona Stock Surges to 52-Week High: What's Behind The Move? - Benzinga
Abeona’s ZEVASKYN Gets FDA Nod for Rare Skin Disease - Contract Pharma
FDA approves Abeona’s Zevaskyn - The Pharma Letter
Abeona prices rare cell disorder gene therapy at $3.1m - Pharmaphorum
Historic achievement: FDA approval of Abeona Therapeutics' ZEVASKYN accelerates momentum and expands treatment options for the EB community. - Olean Times Herald
Stifel lifts Abeona stock target to $21, maintains buy rating By Investing.com - Investing.com Canada
Stifel lifts Abeona stock target to $21, maintains buy rating - Investing.com
FDA Approves Abeona Gene Therapy for Healing Wounds From Rare, Inherited Skin Disease - MedCity News
Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy - insights.citeline.com
Abeona cell therapy approved by FDA for rare skin condition - BioPharma Dive
Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy - Benzinga
Abeona Therapeutics (ABEO) Sees Price Target Boost Amid Zevaskyn - GuruFocus
Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease By Stocktwits - Investing.com India
Cleveland company receives FDA approval for rare disease treatment - Crain's Cleveland Business
FDA Approval of Zevaskyn Boosts ABEO Prospects | ABEO Stock News - GuruFocus
Abeona’s rare skin disease gene therapy approved by FDA - BioWorld MedTech
Abeona Therapeutics (ABEO) Grants Equity Awards to New Employees - GuruFocus
Abeona Therapeutics Says US FDA Approves Zevaskyn to Treat Wounds in Patients With Genetic Skin Disease - marketscreener.com
US FDA approves first cell-based gene therapy for rare genetic skin disorder - Reuters
Abeona Therapeutics Hosts Conference Call and Webcast - TipRanks
FDA Greenlights Abeona Therapeutics' Gene Therapy Zevaskyn for R - GuruFocus
Abeona Therapeutics (ABEO) Jumps on FDA Nod for Gene Therapy Zev - GuruFocus
FDA Approves Abeona Therapeutics' Epidermolysis Bullosa Gene Therapy Pz-Cel - CGTLive®
Abeona stock gains on FDA nod for gene therapy (ABEO:NASDAQ) - Seeking Alpha
FDA Greenlights Abeona Therapeutics' Gene Therapy Zevaskyn for RDEB | ABEO Stock News - GuruFocus
US FDA approves Abeona's skin disorder therapy - marketscreener.com
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the - GlobeNewswire
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) - GlobeNewswire Inc.
Is Abeona Therapeutics Inc (NASDAQ: ABEO) Stock Poised for More Growth? - Marketing Sentinel
How did Abeona Therapeutics Inc (ABEO) fare last session? - uspostnews.com
Global Fanconi Anemia Market Insights: Jasper Therapeutics, - openPR.com
Gaining Ground: Abeona Therapeutics Inc (ABEO) Closes Lower at 4.84, Down -0.21 - DWinneX
Abeona Therapeutics Inc (ABEO) looking to reclaim success with recent performance - Sete News
ABEO Shares Experience Surge in Value - knoxdaily.com
Stock Performance Spotlight: Abeona Therapeutics Inc (ABEO) Ends the Day at 5.22, Down by -1.14 - DWinneX
Examining ABEO’s book value per share for the latest quarter - uspostnews.com
Why Invest In Abeona Therapeutics Inc (ABEO) Stock? - Marketing Sentinel
(ABEO) Investment Analysis and Advice - news.stocktradersdaily.com
Press Release Distribution & PR Platform - ACCESS Newswire
Abeona Therapeutics: pz-cel Has Massive Potential For RDEB Patients - Seeking Alpha
Gaining Ground: Abeona Therapeutics Inc (ABEO) Closes Lower at 4.85, Down -1.42 - DWinneX
Around the Helix: Cell and Gene Therapy Company Updates – April 16, 2025 - CGTLive®
Wellington Management Group LLP Acquires Shares of 93,289 Abeona Therapeutics Inc (NASDAQ:ABEO) - Defense World
Abeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term Upside - Seeking Alpha
Trexquant Investment LP Invests $382,000 in Abeona Therapeutics Inc (NASDAQ:ABEO) - Defense World
FDA Action Alert: Regeneron, Sanofi and Abeona - BioSpace
Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher - Seeking Alpha
0.39%
3.66%
자본화:
|
볼륨(24시간):